• Nenhum resultado encontrado

Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity.

N/A
N/A
Protected

Academic year: 2017

Share "Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity."

Copied!
7
0
0

Texto

Loading

Imagem

Table 1. Clinical features and patient demographics.
Figure 1. Changes in Na + channel associated parameters post-oxaliplatin in motor axons
Figure 2A) in accordance with previous studies [14,15]. In accordance with these changes, RRP was significantly reduced (Pre: 3.960.1 ms; Post: 3.460.2 ms; P,.05)
Table 2. Sensitivity of excitability parameters to oxaliplatin treatment. Parameter Restingvalue  Post-oxaliplatinvalue Percentagedifference P value Motor axons Refractoriness (%) 35.768 75.5621 213% P,.05 Strength-duration time constant (ms) 0.3956.02 0.3
+2

Referências

Documentos relacionados

A tabela 4.8 indica o número de plantas de alpista e respectivas alturas, 8 dias após começo da germinação, para os quatro tipos de sementes (0Gy, 50Gy, 100Gy e 200Gy). Indica também

A intervenção neste ultimo foi baseada na fisioterapia convencional 3x/semana, em sessões de 1 hora, durante 12 semanas, no entanto ao GE foi adicionado 25 minutos de treino

For instance, in a phase II trial the combination of 85 mg/m 2 oxaliplatin on days 1 and 15 plus 80 mg/m 2 irinotecan on days 1, 8, and 15, given every 4 weeks with or

É nesta mudança, abruptamente solicitada e muitas das vezes legislada, que nos vão impondo, neste contexto de sociedades sem emprego; a ordem para a flexibilização como

IV: intravenous; D: day; 5-FU: 5-fluorouracil; G: grade; FOLFOX: oxaliplatin, 5-fluorouracil and leucovorin; mFOLFOX: FOLFOX with different dosage; PO: per oris ; FAC:

In the present study, we investigated the effects of chronic treatment with fl uoxetine in rats treated with oxaliplatin and evaluated the possible quantitative alterations in

Another group of researchers evaluated the role of oral glutamine in 86 patients with metastatic colorectal cancer treated with oxaliplatin (85 mg/m² on days 1 and 15 of each

High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. MicroRNA-18a attenuates DNA